About TB-500 Telehealth: A Reading Room, Not a Waiting Room

What This Site Is

TB-500 Telehealth is a reading room for the published research on the Thymosin Beta-4 heptapeptide and its Ac-LKKTETQ fragment. It summarizes what the studies report, in plain terms, and keeps each summary tied to its citation. For all the 'telehealth' in its name, it holds no consultations and books no visits: there is no appointment line, no clinician on call, and no patient relationship of any kind. Nothing is sold, supplied, prescribed, or dosed here, and no page offers medical advice. What it offers is a cited reading of the literature — a place to read, not a place to be seen.

TB-500 Regulatory Status

TB-500 (Ac-LKKTETQ) is not FDA approved for any human indication. It is a synthetic research compound — the seven-amino-acid active-site fragment of the endogenous protein thymosin beta-4 — and has not completed a published randomized controlled trial in humans as the specific heptapeptide. Phase I human safety data exist for the full-length thymosin beta-4 protein (a distinct 44-amino-acid molecule), administered intravenously in controlled clinical settings ^[11][12].

TB-500 is listed by WADA under Section S2 of the Prohibited List: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. It is prohibited at all times in sanctioned sport. Athletes competing under WADA-compliant anti-doping programs must not use TB-500 or thymosin beta-4. The detection window is approximately 30–45 days in urine and blood ^[1].

This site does not comment on the legality of TB-500 outside competitive sport, which varies by jurisdiction and is not a topic within our editorial scope.

Editorial Methodology

The reading room runs on primary sources. A quantitative claim is set down only when a specific peer-reviewed study, registered trial, or regulatory document backs it, and every reference is listed and checkable. Findings that failed to replicate are read beside those that held, animal results are not reported as proven in people, and vendor copy that conflates the synthetic fragment with full-length Tβ4 is corrected. No seller is linked; the room points outward only to PubMed, ClinicalTrials.gov, the NIH, journals, and the agencies of record. No named clinician stands behind it, and there is no byline, because it reports the record rather than treating from it.